Christopher Peetz sold $2.5M of MIRM
CHIEF EXECUTIVE OFFICER at Mirum Pharmaceuticals, Inc.. 40,000 shares at an average of $62.00, traded Aug 11, 2025, filed Aug 12, 2025.
Score components
- +25RoleCEO
- +25Trade size$2.5M at market
- +5Share of holdings soldSold 22% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-021521, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 11, 2025 | MOption exercise Common Stock10b5-1 | +40,000 | $2.94 | $117k | 178,641 | Aug 12, 2025 |
| Aug 11, 2025 | SOpen-market sale Common Stock10b5-1 | -40,000 | $62.00 | $2.5M | 138,641 | Aug 12, 2025 |
| Aug 11, 2025 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 158,487 | Aug 12, 2025 |
Related signals
Other insiders at Mirum Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $978k 9,943 shares | -18% | |
| 38Weak | Mirum Pharmaceuticals, Inc. | Jolanda Howe SVP, GLOBAL CONTROLLER | $66k 658 shares | -52% | |
| 35Weak | Mirum Pharmaceuticals, Inc. | Christopher Peetz CHIEF EXECUTIVE OFFICER | $3.0M 30,000 shares | -13% | |
| 33Weak | Mirum Pharmaceuticals, Inc. | Michael G Grey director | $3.9M 50,000 shares | -100% | |
| 24Weak | Mirum Pharmaceuticals, Inc. | Saira Ramasastry director | $400k 5,000 shares | -100% | |
| 19Weak | Mirum Pharmaceuticals, Inc. | Saira Ramasastry director | $139k 2,000 shares | -100% | |
| 25Weak | Mirum Pharmaceuticals, Inc. | Michael G Grey director | $3.7M 50,000 shares | -100% | |
| 25Weak | Mirum Pharmaceuticals, Inc. | Michael G Grey director | $3.5M 50,000 shares | -100% | |
| 41Moderate | Mirum Pharmaceuticals, Inc. | Eric Bjerkholt CHIEF FINANCIAL OFFICER | $728k 9,578 shares | -19% | |
| 53Moderate | Mirum Pharmaceuticals, Inc. | Laura Brege director | $1.3M 17,000 shares | -52% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.